Mont-Saint-Guibert (Belgium), Feb. 25 (Korea Bizwire) – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext: NYXH) publishes the below information following the issue of 10,000 new shares on 22 February 2021 pursuant to the exercise of subscription rights. Share capital: EUR 3,797,765.64 Total number of securities [...]
Mont-Saint-Guibert, Belgium, Feb. 24 (Korea Bizwire) – Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the participation of its management team in the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021. Olivier Taelman, CEO [...]
Mont-Saint-Guibert, Belgium, Feb. 9 (Korea Bizwire) – Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces that the Company has received approval by the Food and Drug Administration (FDA) for the Magnetic Resonance Imaging (MRI) conditional [...]
Mont-Saint-Guibert, Belgium, Feb. 2 (Korea Bizwire) – Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the Company has signed an exclusive license agreement with Vandebilt University, Nashville – TN, USA. The agreement allows Nyxoah to [...]
Mont-Saint-Guibert, Belgium, Jan. 26 (Korea Bizwire) – Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the Company has received CE Mark Magnetic Resonance Imaging (MRI) conditional labeling for the current Genio® neurostimulation-based OSA therapy to [...]
Mont-Saint-Guibert, Belgium, Jan. 5 (Korea Bizwire) – Nyxoah S.A. (EBR: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the successful implantation of the first US patient in the DREAM pivotal IDE study. The implantation took place at the [...]
Mont-Saint-Guibert, Belgium, June 25 (Korea Bizwire) - Nyxoah S.A., a healthtech company focused on the development and commercialization of innovative solutions and services to treat sleep disordered breathing conditions, today announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application to allow Nyxoah to commence its pivotal DREAM [...]
Mont-Saint-Guibert, Belgium, Feb. 12 (Korea Bizwire) – Nyxoah S.A., a healthtech company developing neuromodulation-based therapeutic solutions for sleep disordered breathing conditions, today announced that it has raised €25 million in a private financing round. Completion of the financing round is subject to customary closing conditions and is expected to occur later this month. ResMed Inc. [...]